Recap: Accelerate Diagnostics Q3 Earnings
Portfolio Pulse from Benzinga Insights
Accelerate Diagnostics (NASDAQ:AXDX) reported its Q3 earnings, missing estimated earnings by 10.28% with an EPS of $-1.18 versus an estimate of $-1.07. However, revenue was up $339 thousand from the same period last year. Last quarter, the company beat EPS estimates, which was followed by a 2.92% increase in the share price.
November 09, 2023 | 9:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Accelerate Diagnostics missed Q3 earnings estimates but reported increased revenue YoY. Last quarter's EPS beat led to a share price increase.
The company missed earnings estimates, which could negatively impact the stock. However, the increase in revenue and the historical trend of share price increase following an EPS beat could offset this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100